Updated Feb. 22, 2017 at 1:03 p.m.

Premium Lock Argos shares plunge 65% after news it might stop kidney cancer drug trial

Published: 2017-02-22 10:17:00
Updated: 2017-02-22 13:03:23

Argos Argos

​Shares of Argos Therapeutics Inc. fell by more than 65 percent in pre-market trading Wednesday after the drug development company said it received a recommendation from an independent data monitoring committee that the company discontinue the Phase 3 trial for a drug intended to treat kidney cancer....

Read More
Read More

WRAL TechWire any time: Twitter, Facebook

Copyright 2017 The University of North Carolina at Chapel Hill. All rights reserved.
Editor's Blog

Editor's Blog

The latest blog posts from our WRAL TechWire and WRAL editors. Read more articles…

Please Log In to add a comment.

Latest for Insiders